NIAID statement on AstraZeneca vaccine and AstraZeneca update
- Details
- Category: Business
Late Monday, the Data and Safety Monitoring Board (DSMB) notified NIAID, BARDA, and AstraZeneca that it was concerned by information released by AstraZeneca on initial data from its COVID-19 vaccine clinical trial. The DSMB expressed concern that AstraZeneca may have included outdated information from that trial, which may have provided an incomplete view of the efficacy data.
AZD1222 US Phase III trial met primary efficacy endpoint in preventing COVID-19 at interim analysis
- Details
- Category: AstraZeneca
The AstraZeneca US Phase III trial of AZD1222 demonstrated statistically significant vaccine efficacy of 79% at preventing symptomatic COVID-19 and 100% efficacy at preventing severe disease and hospitalisation.
This interim safety and efficacy analysis was based on 32,449 participants accruing 141 symptomatic cases of COVID-19. The trial had a 2:1 randomisation of vaccine to placebo.
Bharat Biotech announces Phase 3 results of COVAXIN®: India's first COVID-19 vaccine demonstrates interim clinical efficacy of 81%
- Details
- Category: Business
Bharat Biotech, a global leader in vaccine innovation, developing vaccines for infectious diseases, announced the first interim analysis of its BBV152 (COVAXIN®). The whole virion inactivated COVID-19 vaccine candidate demonstrated an interim vaccine efficacy of 81% in its Phase 3 clinical trial.
UK and EU regulatory agencies confirm COVID-19 Vaccine AstraZeneca is safe and effective
- Details
- Category: AstraZeneca
Today the Medicines Health Regulatory Authority (MHRA) and European Medicines Agency (EMA) reaffirmed the benefits of COVID-19 Vaccine AstraZeneca continue to far outweigh the risks.
Earlier today, the MHRA announced their review of the small number of thromboembolic events in over 11 million people who received COVID-19 Vaccine AstraZeneca in the UK.
Sanofi and Translate Bio initiate Phase 1/2 clinical trial of mRNA COVID-19 vaccine candidate
- Details
- Category: Sanofi
Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio (NASDAQ: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company, announced the start of the Phase 1/2 clinical trial for MRT5500, an mRNA vaccine candidate against SARS-CoV-2, the virus that causes COVID-19.
WHO statement on AstraZeneca COVID-19 vaccine safety signals
- Details
- Category: Business
Some countries in the European Union have temporarily suspended use of the AstraZeneca COVID-19 vaccine as a precautionary measure based on reports of rare blood coagulation disorders in persons who had received the vaccine. Other countries in the EU - having considered the same information - have decided to continue using the vaccine in their immunization programmes.
Agreement builds on an earlier announcement that included support for the clinical development and supply of the treatment
- Details
- Category: AstraZeneca
AstraZeneca has modified an existing agreement with the US Government to supply up to 500,000 additional doses of AZD7442, a long-acting antibody (LAAB) combination which is in late-stage development for the prevention and treatment of COVID-19.
More Pharma News ...
- First participants dosed in Phase 1 study evaluating mRNA-1283, Moderna's next generation COVID-19 vaccine
- Update on the safety of COVID-19 Vaccine AstraZeneca
- Abbott announces its Pandemic Defense Coalition
- Real-world evidence confirms high effectiveness of Pfizer-BioNTech COVID-19 vaccine and profound public health impact of vaccination one year after pandemic declared
- Abbott introduces NeuroSphere™ Virtual Clinic, first-of-its-kind remote neuromodulation patient-care technology in the U.S.
- EMA issues advice on Lilly's bamlanivimab (LY-CoV555) alone and administered together with etesevimab (LY-CoV016) for the treatment of confirmed COVID-19 in the European Union
- Johnson & Johnson announces aingle-ahot Janssen COVID-19 vaccine candidate met primary endpoints in interim analysis of its Phase 3 ENSEMBLE trial